Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

FDA grants Orphan Drug Designation for anti-diabetic drug

The FDA has granted Orphan Drug Designation of Diamyd Medical´s lead drug candidate Diamyd®. Orphan drugs qualify for seven years of market exclusivity from the date of US marketing approval, tax credits for clinical research and a waiver for FDA user fees.

24 Mar 2010

T1D and IBD may respond to 2-way genetic switch: Study

Pediatric researchers analyzing DNA variations in type 1 diabetes and inflammatory bowel disease have found a complex interplay of genes. Some genes have opposing effects, raising the risk of one disease while protecting against the other. In other cases, a gene variant may act in the same direction, raising the risk for both diseases.

23 Mar 2010

Diabetic Pennsylvanians can reduce risk of complications by following "ABCs" of diabetes

Secretary of Health Everette James reminds diabetic Pennsylvanians to reduce the risk of complications from the disease and improve their quality of life by knowing and following the "ABCs" of diabetes.

23 Mar 2010

Walnuts affect genes related to prostate tumor growth: Study

Walnut consumption slows the growth of prostate cancer in mice and has beneficial effects on multiple genes related to the control of tumor growth and metabolism, UC Davis and the U.S. Department of Agriculture Western Regional Research Center in Albany, Calif. have found.

23 Mar 2010

JDRF, Pfizer, Hadassah Medical Organization, The Hebrew University of Jerusalem form diabetes research collaboration

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes.

22 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

JDRF to begin diabetes research collaboration on drugs for replicating insulin-producing cells

22 Mar 2010

CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement

Richard S. Rofe, who serves as Managing Director for Arcadia Capital Advisors, LLC, and is part of a shareholder group that includes Arcadia with a 9.97 percent ownership interest in CPEX Pharmaceuticals, Inc.,, commented on CPEX's recent announcement of failed Phase 2a Nasulin study results.

19 Mar 2010

Lifestyle improvements and new treatments for diabetes and cardiovascular disease needed

Treatment with the anti-hypertensive drug valsartan (Diovan) led to a modest reduction in the development of type 2 diabetes but did not significantly reduce cardiovascular events in patients with impaired glucose tolerance, according to researchers at Duke University Medical Center and the University of Oxford. They jointly reported results at the American College of Cardiology meeting today from the world's first study designed to find ways to control the progression to diabetes and cardiovascular disease in people at risk.

19 Mar 2010

JDRF hosts Diabetes Research Symposium to focus on type 1 diabetes

For the second consecutive year in Montreal, Juvenile Diabetes Research Foundation's Diabetes Research Symposium will be opening its doors at Fairmont Queen Elizabeth this Sunday, March 21st, from 1:00 p.m. to 4:00 p.m. Free and open to all, this event will focus on type 1 (juvenile) diabetes, and aims to inform the general public about JDRF's groundbreaking research progress.

19 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

New specialty service at Montefiore Medical Center helps patients with drug allergies

A Westchester patient takes aspirin for pain, but develops rashes and hives. A Bronx patient with a gastrointestinal problem caused by bacteria is prescribed penicillin, then passes out. A Bronx woman is given a contrast dye for an internal diagnostic exam, then her skin peels off.

18 Mar 2010

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.

18 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

ONGLYZA-metformin combination: FDA accepts NDA for review

Bristol-Myers Squibb Company and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose combination of ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor, and metformin HCl extended-release tablets as a once-daily treatment for type 2 diabetes mellitus in adults.

17 Mar 2010

FDA approves Medtronic's MiniMed Paradigm integrated diabetes management system

Medtronic, Inc. today announced it has received U.S. Food and Drug Administration (FDA) approval for the MiniMed Paradigm® REAL-Time Revel™ System, the next generation of the industry’s only integrated diabetes management system (insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software).

17 Mar 2010

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Generex Biotechnology Corporation (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Philip Raskin, MD, of The University of Texas Southwestern Medical Center in Dallas, Texas, made a presentation in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension held in Buenos Aires, Argentina, March 11-14, 2010 (www.comtecmed.com/Codhy/argentina).

17 Mar 2010

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3).

16 Mar 2010

'Molecular band-aid' may help protect hearts of Duchenne muscular dystrophy patients

Researchers at the University of Minnesota Medical School have discovered a chemical that may, over the long term, protect the hearts of Duchenne muscular dystrophy patients - a fatal and most common form of muscular dystrophy in children.

16 Mar 2010

Workings of IGFs on muscle cells

The muscle-building abilities of hormones known as insulin-like growth factors (IGFs) are legendary. Just do an online search and you'll find not only scientific papers discussing the effects of IGFs on the cells that give rise to muscle tissue, but also scores of ads touting the purported benefits of IGF supplements for bodybuilding.

16 Mar 2010

Insulin News and Research

Further Reading

FDA grants Orphan Drug Designation for anti-diabetic drug

T1D and IBD may respond to 2-way genetic switch: Study

Diabetic Pennsylvanians can reduce risk of complications by following "ABCs" of diabetes

Walnuts affect genes related to prostate tumor growth: Study

JDRF, Pfizer, Hadassah Medical Organization, The Hebrew University of Jerusalem form diabetes research collaboration

ChemoCentryx undertakes Phase II clinical trial of CCX140

JDRF to begin diabetes research collaboration on drugs for replicating insulin-producing cells

CPEX Pharmaceuticals' Phase 2a Nasulin trial fails, Arcadia Capital Advisors issues statement

Lifestyle improvements and new treatments for diabetes and cardiovascular disease needed

JDRF hosts Diabetes Research Symposium to focus on type 1 diabetes

NexACT technology demonstrates ability to deliver Taxol subcutaneously

New specialty service at Montefiore Medical Center helps patients with drug allergies

Alzheimer's disease: Gene expression level influences promotion of disorder or protection against development

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

ONGLYZA-metformin combination: FDA accepts NDA for review

FDA approves Medtronic's MiniMed Paradigm integrated diabetes management system

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Tolerx publishes follow-up data from study of otelixizumab therapy for new onset T1DM patients

'Molecular band-aid' may help protect hearts of Duchenne muscular dystrophy patients

Workings of IGFs on muscle cells

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News